The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of ...

Key Takeaways SYK Q2 EPS of $3.13 and revenues of $6.02B beat estimates, led by 17% growth in MedSurg and Neurotechnology.SYK raised 2025 EPS guidance to $13.45-$13.60 and sees 9.5-10% organic revenue growth for the full year.SYK gross margin rose 110 bps to 65.3% on pricing and supply-chain gains despite higher operating expenses.Stryker Corporation (SYK) reported second-quarter 2025 adjusted earnings per share (EPS) of $3.13, which beat the Zacks Consensus Estimate of $3.06 by 2.3%. The bottom line also i ...

CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company’s aprevo® personalized interbody implants. The NTAP program is d ...

Butterfly Network (BFLY) Q2 2025 Earnings Call August 01, 2025 08:00 AM ET Speaker0Hello, everyone, and welcome to the Butterfly Network Second Quarter twenty twenty five Earnings Call. My name is Carla, and I will be coordinating your call today. During the presentation, you can register to ask questions by pressing star followed by one on your telephone keypad. I would now like to hand you over to your host, Heather Gatz, to begin. Heather, please go ahead when you're ready.Speaker1Good morning, and thank ...

Key Takeaways RMD's Q4 adjusted EPS rose 22.6% to $2.55, beating estimates and driven by strong global performance.RMD's revenues grew 10.2% to $1.35B, fueled by solid gains in devices, masks and Residential Care Software.RMD's adjusted gross margin rose 227 bps to 61.4%, supported by cost efficiencies and currency tailwinds.Resmed Inc.’s (RMD) adjusted earnings per share (EPS) in the fourth quarter of fiscal 2025 were $2.55, up 22.6% year over year. The metric beat the Zacks Consensus Estimate by 3.66%.The ...

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share ...

WARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the US launch and first surgical case of the new 3P™ Pediatric Plating Platform™ Hip System, used to treat proximal femur fractures and deformities. “The 3P Pediatric Plating Platform Hip System is an exceptional product that would not be possible without our remarkable design surgeons and dev ...

MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule. “We appreciate CMS’ openness to public comment on the proposed rule an ...

债务股权转换交易 - 公司通过发行4,162,500股普通股（每股作价0 01美元）抵消41,625美元债务 四位董事分别获得股份 Etienne Grima获1,192,500股（抵消11,925美元） Robert Caines获1,230,000股（抵消12,300美元） Daniel Grima获1,080,000股（抵消10,800美元） Robin Black获660,000股（抵消6,600美元）[1] - 债务源于董事在2024年及2025年上半年提供的服务[1] 股份限售规定 - 发行的股份受四个月限售期约束 至2025年12月1日到期 符合TSX Venture Exchange政策及证券法规[2] 关联交易豁免 - 债务结算属于关联交易 但豁免MI 61-101要求的正式估值及少数股东批准程序 因每笔交易公允价值未超过公司市值的25[3] 公司业务概述 - 公司专注于心电监测及ECG软件解决方案 产品用于记录 查看 分析及存储心电图数据 服务于心脏疾病诊断与管理[5] - 产品通过北美销售团队及全球分销网络销售 持有FDA和加拿大卫生部医疗设备许可 符合ISO 13485 ISO 27001及HIPAA认证[5] 信息披露渠道 - 公司官网提供产品详情及更新信息 包括www cardiocommsolutions com和www theheartcheck com[4]

ResMed (RMD) Q4 2025 Earnings Call July 31, 2025 04:30 PM ET Company ParticipantsSalli Schwartz - Chief Investor Relations OfficerMichael Farrell - CEO & ChairmanBrett Sandercock - CFOCraig Wong-Pan - Director - Equity ResearchAnthony Petrone - MD - Equity ResearchMatt Taylor - Managing DirectorConference Call ParticipantsDan Hurren - Healthcare AnalystDavinthra Thillainathan - Healthcare Equity AnalystSaul Hadassin - Analyst - Healthcare ServicesDavid Bailey - Equity Research AnalystBrett Fishbin - VP - Se ...